Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CV SciencesCVSI -3.79% 3-Year EBITDA Growth Rate is 71.20% as of Jun. 2026, which is 649% above its 10-year median of 9.50. The stock has 3 warning signs investors should review. Among 808 Drug Manufacturers companies, CV Sciences ranks better than 93.94% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 71.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CV Sciences was 71.20% per year. The lowest was -265.10% per year. And the median was 9.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CV Sciences 3-Year EBITDA Growth Rate Related Terms
CVSI vs AKAN, SNOA, CTTH: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CV Sciences 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CV Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CV Sciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 71.20% mean?
CV Sciences (CVSI) has a 3-Year EBITDA Growth Rate of 71.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CV Sciences and its competitors. This is 649% above median its historical median of 9.50. According to the industry distribution chart, CV Sciences ranks #49 out of 808 companies in the Drug Manufacturers industry, placing it in the top 6.1%.
Is CV Sciences' 3-Year EBITDA Growth Rate too high?
CV Sciences' current 3-Year EBITDA Growth Rate of 71.20% is 649% above median its 10-year median of 9.50. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. CV Sciences' value of 71.20% is 709.1% above this industry median. Based on the distribution chart, CV Sciences ranks #49 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CV Sciences' 3-Year EBITDA Growth Rate compare to AKAN and SNOA?
According to the Drug Manufacturers industry distribution chart, CV Sciences ranks #49 out of 808 companies for 3-Year EBITDA Growth Rate. This places CV Sciences in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. CV Sciences' value of 71.20% is 709.1% above this benchmark. While the company's 10-year median is 9.50 vs. the industry median of 8.80, CV Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CV Sciences's current 3-Year EBITDA Growth Rate of 71.20% is 709.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CV Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CV Sciences's current 3-Year EBITDA Growth Rate is 71.20%, which is 649% above median its own 10-year median of 9.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CV Sciences stock overvalued right now?
Based on GuruFocus' analysis, CV Sciences (CVSI) is currently considered Possible Value Trap. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 40.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 71.20%, which is 649% above median its 10-year median of 9.50 and 709.1% above the Drug Manufacturers industry median of 8.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CV Sciences (CVSI), the current 3-Year EBITDA Growth Rate is 71.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CV Sciences Inc is a consumer wellness company specializing in nutraceuticals and plant-based foods products. It develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The company sells its products under tradenames, such as +PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox. The company's products are sold in a variety of market sectors, including nutraceutical, beauty care, and specialty foods. The company has one operating segment, which is the business of hemp-based CBD wellness products. Geographically, all of the company's revenue is generated from United States. The company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVSI has been successfully added to your 
